Investment analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 1.9 %
Shares of NASDAQ:AKTX opened at $1.10 on Tuesday. Akari Therapeutics has a one year low of $0.85 and a one year high of $4.40. The business’s 50-day simple moving average is $1.11 and its 200 day simple moving average is $1.80.
About Akari Therapeutics
Further Reading
- Five stocks we like better than Akari Therapeutics
- How Technical Indicators Can Help You Find Oversold StocksÂ
- Can TikTok Stock Picks Really Make You Rich?
- The Risks of Owning Bonds
- The “Quality” Rotation: Back to Basics Investing
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.